NF110 

NF110 is a P2X₃ receptor antagonist (K_i = 36 nM) and inactive toward P2Y receptors stably expressed (IC₅₀s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC₅₀ = 527 nM) in rat dorsal root ganglia neurons^[1].

Ki: 36 nM (P2X3 Receptor)

NF110 shows an activity in the human tumour cell line panel, with IC₃₀ of 362.3 μM^[2].
NF110 inhibits HMGA2-DNA interactions with an IC₅₀ of 0.87 μM^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

NF110 shows potency at Endogenous P2X Receptors in Rat DRG Neurons, with a peak amplitude of 675 pA^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1096.91

C₄₁H₂₈N₆Na₄O₁₇S₄

111150-22-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hausmann R, et al. The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol  [Content Brief]

  [2]. Dhar S, et al. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer. 2000;36(6):803-809.  [Content Brief]

  [3]. Su L, et al. Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. Sci Rep. 2020;10(1):18850. Published 2020 Nov 2.  [Content Brief]